Annals of Surgical Oncology

, Volume 13, Issue 3, pp 405–412 | Cite as

Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy: Results of a Prospective Study

  • C. Brigand
  • O. Monneuse
  • F. Mohamed
  • A. C. Sayag-Beaujard
  • S. Isaac
  • F. N. Gilly
  • O. Glehen
Original Article



Peritoneal mesothelioma is a rare disease with few therapeutic options. Recently, the combination of cytoreductive surgery with intraperitoneal hyperthermic chemotherapy (HIPEC) has shown promising results.


Fifteen patients with peritoneal mesothelioma who were treated by cytoreductive surgery and HIPEC between 1989 and 2004 were identified from a prospective database. HIPEC was performed with cisplatin and mitomycin C for 90 minutes by using the closed-abdomen technique.


All patients but one (multicystic) had malignant disease of the following pathologic types: 12 epithelial and 2 biphasic. After surgical resection, 11 patients were considered to have a CC-0 or CC-1 resection (macroscopic complete resection or diameter of residual nodules <2.5 mm). No postoperative death occurred, and six postoperative complications were recorded. All but one patient had resolution of ascites. The overall median survival for the 14 patients with malignant mesothelioma was 35.6 months. The median survival was 37.8 months for patients treated with a CC-0 or CC-1 resection, whereas it was 6.5 months for those treated with a CC-2 or CC-3 resection (diameter of residual nodules >2.5 mm; P < .001). In a univariate analysis, the only other significant prognostic factor was the carcinomatosis extent (P = .02).


A therapeutic strategy combining cytoreductive surgery with HIPEC seems to provide an adequate and efficient locoregional treatment for peritoneal mesothelioma. It is associated with acceptable morbidity when performed by an experienced surgical team. The completeness of cytoreduction is the major determinant of survival.


Peritoneal mesothelioma Cytoreductive surgery Intraperitoneal chemotherapy Hyperthermia Peritoneal carcinomatosis Survival 


  1. 1.
    Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 1988;6:147–53PubMedGoogle Scholar
  2. 2.
    Asensio JA, Goldblatt P, Thomford NR. Primary malignant peritoneal mesothelioma. A report of seven cases and a review of the literature. Arch Surg 1990;125:1477–81PubMedGoogle Scholar
  3. 3.
    Neumann V, Rutten A, Scharmach M, Muller KM, Fischer M. Factors influencing long-term survival in mesothelioma patients—results of the German mesothelioma register. Int Arch Occup Environ Health 2004;77:191–9CrossRefPubMedGoogle Scholar
  4. 4.
    Peterson JT Jr, Greenberg SD, Buffler PA. Non-asbestos-related malignant mesothelioma. A review. Cancer 1984;54:951–60PubMedGoogle Scholar
  5. 5.
    Sugarbaker PH, Welch L, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin North Am 2003;12:605–21Google Scholar
  6. 6.
    Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560–7CrossRefPubMedGoogle Scholar
  7. 7.
    Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003;89:269–73PubMedGoogle Scholar
  8. 8.
    Antman KH, Blum RH, Greenberger JS, et al. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980;68:356–62CrossRefPubMedGoogle Scholar
  9. 9.
    Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221:29–42PubMedGoogle Scholar
  10. 10.
    Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004;5:219–28CrossRefPubMedGoogle Scholar
  11. 11.
    Yonemura Y, Fujimura T, Nishimura G, et al. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery 1996;119:437–44PubMedGoogle Scholar
  12. 12.
    Elias D, Pocard M. Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Clin North Am 2003;12:543–59Google Scholar
  13. 13.
    Crile G. The effect of heat and radiation on cancers implanted in the feet of mice. Cancer Res 1963;23:372–80PubMedGoogle Scholar
  14. 14.
    Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998;14:254–61CrossRefPubMedGoogle Scholar
  15. 15.
    Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 1980;40:1165–8PubMedGoogle Scholar
  16. 16.
    Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC. Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res 1981;41:1096–9PubMedGoogle Scholar
  17. 17.
    Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003;21:799–806CrossRefPubMedGoogle Scholar
  18. 18.
    Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998;69:103–8CrossRefPubMedGoogle Scholar
  19. 19.
    Ruth S, Verwaal VJ, Hart AA, van Slooten GW, Zoetmulder FA. Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy. Anticancer Res 2003;23:1501–8PubMedGoogle Scholar
  20. 20.
    Loggie BW, Fleming RA, McQuellon RP, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001;67:999–1003PubMedGoogle Scholar
  21. 21.
    Deraco M, Casali P, Inglese MG, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 2003;83:147–53CrossRefPubMedGoogle Scholar
  22. 22.
    Gilly FN, Carry PY, Sayag AC, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 1994;41:124–9PubMedGoogle Scholar
  23. 23.
    Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727–31CrossRefPubMedGoogle Scholar
  24. 24.
    Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet 2004;364:1183–5CrossRefPubMedGoogle Scholar
  25. 25.
    Averbach AM, Sugarbaker PH. Peritoneal mesothelioma: treatment approach based on natural history. Cancer Treat Res 1996;81:193–211PubMedGoogle Scholar
  26. 26.
    Wagner JC, Sleegs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960;17:260–71PubMedGoogle Scholar
  27. 27.
    Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001;357:444–5PubMedGoogle Scholar
  28. 28.
    Mohamed F, Sugarbaker PH. Peritoneal mesothelioma. Curr Treat Options Oncol 2002;3:375–86PubMedGoogle Scholar
  29. 29.
    Sridhar KS, Doria R, Raub WA Jr, Thurer RJ, Saldana M. New strategies are needed in diffuse malignant mesothelioma. Cancer 1992;70:2969–79PubMedGoogle Scholar
  30. 30.
    Rose RG, Palmer JD, Lougheed MN. Treatment of peritoneal mesothelioma with radioactive colloidal gold; report of a case. Cancer 1955;8:478–81PubMedGoogle Scholar
  31. 31.
    Rogoff EE, Hilaris BS, Huvos AG. Long-term survival in patients with malignant peritoneal mesothelioma treated with irradiation. Cancer 1973;32:656–64PubMedGoogle Scholar
  32. 32.
    Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992;118:547–50PubMedGoogle Scholar
  33. 33.
    Langer CJ, Rosenblum N, Hogan M, et al. Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach. Cancer Chemother Pharmacol 1993;32:204–8CrossRefPubMedGoogle Scholar
  34. 34.
    Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000;87:1587–93CrossRefPubMedGoogle Scholar
  35. 35.
    Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999;70:6–12CrossRefPubMedGoogle Scholar
  36. 36.
    Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284–92CrossRefPubMedGoogle Scholar
  37. 37.
    Barakat RR, Sabbatini P, Bhaskaran D, et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 2002;20:694–8CrossRefPubMedGoogle Scholar
  38. 38.
    Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005;10:112–22CrossRefPubMedGoogle Scholar
  39. 39.
    Sayag AC, Gilly FN, Carry PY, et al. Intraoperative chemohyperthermia in the management of digestive cancers. A general review of literature. Oncology 1993;50:333–7PubMedGoogle Scholar
  40. 40.
    Glehen O, Osinski D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003;10:863–9CrossRefPubMedGoogle Scholar
  41. 41.
    Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999;6:790–6CrossRefPubMedGoogle Scholar
  42. 42.
    Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 2005;103:839–49CrossRefPubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2006

Authors and Affiliations

  • C. Brigand
    • 1
  • O. Monneuse
    • 2
    • 3
  • F. Mohamed
    • 4
  • A. C. Sayag-Beaujard
    • 5
  • S. Isaac
    • 6
  • F. N. Gilly
    • 3
    • 7
  • O. Glehen
    • 3
    • 7
  1. 1.Department of General SurgeryCentre Hospitalier Universitaire de StrasbourgFrance
  2. 2.Department of Emergency SurgeryHôpital Edouard HerriotFrance
  3. 3.Equipe Accueil 3738Faculté de Médecine Lyon-SudFrance
  4. 4.Department of General SurgeryNewcastle upon TyneUnited Kingdom
  5. 5.Department of AnesthesiologyCentre Hospitalier Lyon-SudFrance
  6. 6.Department of PathologyCentre Hospitalier Lyon-SudFrance
  7. 7.Department of Surgical OncologyCentre Hospitalier Lyon-SudFrance

Personalised recommendations